1
Clinical Trials associated with Personalized Mutation-derived Tumor Vaccine(NovoCure) / Active, not recruitingPhase 1IIT Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)
The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields).
The study is designed to determine whether this treatment combination is well tolerated and safe.
100 Clinical Results associated with Personalized Mutation-derived Tumor Vaccine(NovoCure)
100 Translational Medicine associated with Personalized Mutation-derived Tumor Vaccine(NovoCure)
100 Patents (Medical) associated with Personalized Mutation-derived Tumor Vaccine(NovoCure)
100 Deals associated with Personalized Mutation-derived Tumor Vaccine(NovoCure)